Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Re-Thinking Rare Disease

Sep 13 2022

• By Melanie Senior

Swan — Orphan drugs are classified as those destined for fewer than five in 10,000 people in Europe • Source: Shutterstock

Related Content

Gene Therapy Pricing To Come Under Microscope In Germany

Nov 17 2021

Bluebird Exits Europe, Casting Clouds Over Gene Therapy Commercial Effort

Aug 09 2021

Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law

Aug 16 2022

Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise

Aug 08 2022

Germany: Leaked Pricing Measures Could Have ‘Drastic’ Consequences For Orphans

Jul 07 2022

Germany To Honor Pledge To Cut Spending On Medicines

Mar 17 2022

Related Companies

Johnson & Johnson

Genetix Biotherapeutics

Insmed Incorporated

Merck & Co., Inc.

Novartis AG

Spark Therapeutics, Inc.

Pfizer Inc.

IQVIA Holdings Inc.

Additional Topics

Germany Europe United States Cost Effectiveness Rare Diseases Reimbursement Regenerative Medicine Strategy Market Access Legislation FDA Gene Therapy BioPharmaceutical

More from Market Access

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window